Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-35
RECRUITING1
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ENDOSTAR,cisplatin NCT04914598 |
P3 | Active, not recruiting | Malignant Pleural Effusion | 290 | 2025-02-10 (+31 mo) |
| SIM0278 injection NCT07175233 |
P2 | Active, not recruiting | Atopic Dermatitis (AD) | 184 | 2026-09-23 (+1 mo) |
| TRACER NCT07881705 |
P3 | Active, not recruiting | Myelosuppression | 106 | 2027-07-15 |
| Suvemcitug injection, trifluridine/tipiracil tablets NCT07361003 |
P3 | Recruiting | Refractory Metastatic Colorectal Cancer | 464 | 2028-01 |
| SIM0270 NCT06680921 |
P3 | Active, not recruiting | Locally Advanced or Metastatic Breast Cancer | 482 | 2028-08-31 |
| SIM0811 Dose Level A (Phase II) NCT07903701 |
P2/3 | Not yet recruiting | Acute Ischemic Stroke AIS | 1092 | 2029-06-30 |